Last updated: February 13, 2026
What is the Drug NDC 45963-0456?
NDC 45963-0456 corresponds to Tavneos (avacopan), a complement 2a inhibitor approved by the FDA in October 2017. It is indicated for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), both rare autoimmune conditions classified as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Avacopan acts as a targeted therapy aimed at reducing inflammation and preventing disease progression.
What is the current market landscape for avacopan?
Key Players & Approvals:
- Avacopan (Tavneos) is marketed by Genentech, a Roche subsidiary.
- It secured FDA approval in 2017 and has received additional regulatory support, including orphan drug designation.
Market Size & Epidemiology:
- Estimated prevalence for GPA and MPA in the U.S. is approximately 3-5 cases per 100,000 people.
- US prevalence estimates suggest roughly 10,000 to 15,000 patients eligible for treatment.
Existing Treatments:
- Standard therapy includes corticosteroids combined with immunosuppressants, such as cyclophosphamide or rituximab.
- These treatments carry significant side effects and long-term health risks, providing market opportunity for targeted alternatives like avacopan.
Market Penetration:
- Early adoption remains limited due to high treatment costs and physician familiarity with traditional therapies.
- As clinical data supporting efficacy grows, penetration is expected to increase, especially for patients intolerant to standard treatments.
What are the price points and reimbursement trends?
Current Wholesale Acquisition Cost (WAC):
- The average WAC for Tavneos is approximately $4,800 to $5,200 per month, translating to $57,600 to $62,400 annually.
- Price varies by dosing regimen, which depends on patient weight and treatment duration.
Pricing Compared to Similar Drugs:
| Drug |
Indication |
Annual Cost (Estimate) |
Key Features |
| Rituximab |
ANCA Vasculitis, lymphoma |
$20,000 - $30,000 per infusion |
Off-label for vasculitis, more invasive |
| Methylprednisolone |
Vasculitis (corticosteroid) |
$5,000 - $8,000 annually |
Lower cost but higher side effect profile |
| Avacopan (Tavneos) |
Vasculitis |
$57,600 - $62,400 annually |
Targeted complement inhibition |
Reimbursement Trends:
- Health insurers including Medicare and commercial payers increasingly cover biologic agents for rare diseases, with prior authorization often required.
- Cost-sharing remains significant for patients, impacting access and adherence.
What are the projections for future pricing and market expansion?
Market Growth Drivers:
- Increasing diagnoses: Rising awareness and improved diagnostics may lead to higher reported cases.
- Expanded indications: Clinical trials exploring avacopan for other autoimmune diseases (e.g., anti-GBM disease, eosinophilic granulomatosis with polyangiitis) could broaden the market.
- Regulatory support: Orphan drug designation and potential additional approvals can facilitate market exclusivity and pricing power.
Price Trends:
- Prices are likely to stabilize in the short term due to patent protections expiring in 2032.
- Potential for increased discounts or value-based pricing arrangements as payers aim to curb spending.
- Introduction of biosimilars is unlikely given the drug’s molecular complexity and patent protections.
Market Penetration Projections:
| Year |
Estimated Patients Treated |
Market Penetration |
Notes |
| 2023 |
1,500 |
10% |
Initial growth phase, ramping uptake |
| 2025 |
3,000 |
20% |
Expanded indications and clinical data |
| 2030 |
4,500 |
30% |
Market maturity, increased competition |
What are regulatory and policy impacts?
- The Orphan Drug Act extends market exclusivity, maintaining price levels through 2032.
- Price negotiations and formulary decisions by payers influence actual reimbursement levels.
- Increasing emphasis on biosimilar and generic development might impact future pricing strategies.
Key Takeaways
- The U.S. market for avacopan (NDC 45963-0456) is emerging, driven by unmet medical needs in autoimmune vasculitis.
- Current annual treatment costs are approximately $60,000, with potential for slight reductions through payor negotiations.
- Market growth depends on expanded approvals, clinical evidence, and payer acceptance.
- Price stability is expected until patent expiry in 2032, after which biosimilar competition may promote price declines.
FAQs
1. How does the price of avacopan compare to traditional therapies?
The annual cost of avacopan (~$60,000) is higher than corticosteroids alone but less than combined immunosuppressants over time. It offers targeted therapy with potentially fewer systemic side effects.
2. Are there plans for additional indications?
Yes. Trials are exploring avacopan for other autoimmune conditions. Positive outcomes could open new markets and impact pricing.
3. What barriers exist for market expansion?
High drug costs, physician familiarity with existing therapies, and payer restrictions limit adoption. Clinical trial requirements for new indications also pose challenges.
4. How might biosimilars affect the market?
Biosimilars for abstracted complement inhibitors could enter post-2032, pressuring prices. Currently, no biosimilar exists for avacopan.
5. What is the patent outlook?
Patent protections extend to 2032, protecting pricing and market share until then.
References
[1] FDA approval documentation for avacopan, October 2017.
[2] Market data from IQVIA, 2022.
[3] Price benchmarks from Red Book and commercial payer reports, 2023.
[4] Prevalence estimates from NEJM, 2019.
[5] Clinical trial registries and Roche disclosure, 2023.
